EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current status of precision oncology in adult glioblastoma

Johannes Weller, Anna-Laura Potthoff iD, Thomas Zeyen, Christina Schaub, Cathrina Duffy, Matthias Schneider iD, Ulrich Herrlinger iD

Molecular Oncology · 2024-12 · 18 (12) · 2927-2950

DOI: 10.1002/1878-0261.13678 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Oncology, online erschienen am 20.06.2024. Verfasst von Johannes Weller und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurooncology, Center for Neurology, University Hospital Bonn, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Precision Medicine, Brain Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 217 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The concept of precision oncology, the application of targeted drugs based on comprehensive molecular profiling, has revolutionized treatment strategies in oncology. This review summarizes the current status of precision oncology in glioblastoma (GBM), the most common and aggressive primary brain tumor in adults with a median survival below 2 years. Targeted treatments without prior target verification have consistently failed. Patients with BRAF V600E‐mutated GBM benefit from BRAF/MEK‐inhibition, whereas targeting EGFR alterations was unsuccessful due to poor tumor penetration, tumor cell heterogeneity, and pathway redundancies. Systematic screening for actionable molecular alterations resulted in low rates (< 10%) of targeted treatments. Efficacy was observed in one‐third and currently appears to be limited to BRAF‐, VEGFR‐, and mTOR‐directed treatments. Advancing precision oncology for GBM requires consideration of pathways instead of single alterations, new trial concepts enabling rapid and adaptive drug evaluation, a focus on drugs with sufficient bioavailability in the CNS, and the extension of target discovery and validation to the tumor microenvironment, tumor cell networks, and their interaction with immune cells and neurons.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaPrecision MedicineBrain NeoplasmsHumansAdultMolecular Targeted TherapyMedical Oncology

Stichwörter der Autor:innen

biomarkerglioblastomamolecular profilingpersonalized medicineprecision oncologytargeted treatment

Autor:innen und Institutionen

  • Department of Neurooncology, Center for Neurology, University Hospital Bonn, Germany.
  • Department of Neurosurgery, University Hospital Bonn, Germany.

ORCID-Profile: Anna-Laura Potthoff, Matthias Schneider, Ulrich Herrlinger

Zitieren

APA

Weller, J., Potthoff, A. L., Zeyen, T., Schaub, C., Duffy, C., Schneider, M., & Herrlinger, U. (2024). Current status of precision oncology in adult glioblastoma. Molecular Oncology, 18(12), 2927-2950. https://doi.org/10.1002/1878-0261.13678

Vancouver

Weller J, Potthoff AL, Zeyen T, Schaub C, Duffy C, Schneider M, et al. Current status of precision oncology in adult glioblastoma. Molecular Oncology. 2024;18(12):2927-2950. doi:10.1002/1878-0261.13678

BibTeX
@article{Weller2024,
  author = {Weller, Johannes and Potthoff, Anna-Laura and Zeyen, Thomas and Schaub, Christina and Duffy, Cathrina and Schneider, Matthias and Herrlinger, Ulrich},
  title = {Current status of precision oncology in adult glioblastoma},
  journal = {Molecular Oncology},
  year = {2024},
  volume = {18},
  number = {12},
  pages = {2927--2950},
  doi = {10.1002/1878-0261.13678}
}
Kostenlos starten →